Company Strategy
Company origin
- Theripion, Inc. is a privately held, Seattle-based biotechnology company focused on targeted rescue enzyme therapy applicable to multiple diseases. We are at the pre-clinical stage optimizing our lead molecules with the goal of propelling our innovations into the clinic.
- We have focused on generation of intellectual property and have secured patent protection on Ther4 and bispecific Ther4-PON 1 fusion molecules in several jurisdictions with other patent applications pending.
- We have and continue to pursue preclinical studies in animal models of disease to provide proof-of-concept.
Commercialization
- We would like to collaborate with leading biopharmaceutical companies to continue clinical development of our lead molecules.
- We envision obtaining funding to pursue production of material for toxicity studies that can lead to an IND from the FDA.
- The following step would be to generate GMP material to take into the clinic for studies in man.
- We would like to partner with companies that can help propel our lead molecules into FDA approved products that provide significant help to patients in need of these therapies.